Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydia Scarfò

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
Blood Advances|April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohortAndrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Cancers|March 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE StudyFrancesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Hemasphere|February 18, 2026
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformationChiara Cosentino, Samir Mouhssine, Antonella Zucchetto, et al.
The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.
The Lancet. Haematology|April 1, 2016
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre studyPanagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton, et al.
Blood|January 31, 2015
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsPanagiotis Baliakas, Andreas Agathangelidis, Anastasia Hadzidimitriou, et al.
Haematologica|January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS studyFrancesca R Mauro, Irene Della Starza, Monica Messina, et al.
Leukemia|September 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC studyAndrea Visentin, Enrico Gaffo, Moritz Fürstenau, et al.
Blood Advances|May 27, 2026
Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevanceHelen Parker, Amatta Mirandari, Ben Stevens, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
Blood Advances|April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohortAndrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Cancers|March 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE StudyFrancesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Hemasphere|February 18, 2026
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformationChiara Cosentino, Samir Mouhssine, Antonella Zucchetto, et al.
The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.
The Lancet. Haematology|April 1, 2016
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre studyPanagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton, et al.
Blood|January 31, 2015
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsPanagiotis Baliakas, Andreas Agathangelidis, Anastasia Hadzidimitriou, et al.
Haematologica|January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS studyFrancesca R Mauro, Irene Della Starza, Monica Messina, et al.
Leukemia|September 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC studyAndrea Visentin, Enrico Gaffo, Moritz Fürstenau, et al.
Blood Advances|May 27, 2026
Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevanceHelen Parker, Amatta Mirandari, Ben Stevens, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Pageof 12